NCAM1 and plasma cell myeloma: Currently, huN901-DM1-based anti-NCAM treatments of small cell lung cancer, NCAM-positive solid tumors and multiple myeloma are in phase I/II clinical studies http://www.immunogen.com/wt/page/IMGN901b.